AbCellera Biologics Inc. in 1 story
The narratives ABCL currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for ABCL yet.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
ABCL in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Its early-stage antibody-discovery model faces competition for pharmaceutical budgets when buyers can instead license clinically de-risked molecules from China.